<DOC>
	<DOCNO>NCT01140503</DOCNO>
	<brief_summary>This study design evaluate safety efficacy oral medicine ( call apremilast ) treat skin involvement patient disease dermatomyositis .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Apremilast Treatment Skin Disease Patients With Dermatomyositis</brief_title>
	<detailed_description />
	<mesh_term>Dermatomyositis</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Must understand voluntarily sign informed consent form Must 18 year time signing informed consent form Must able adhere study visit schedule protocol requirement Patients must diagnosis DM base upon characteristic cutaneous finding propose Sontheimer1 skin biopsy consistent DM Subjects must candidate systemic therapy DM skin disease : subject consider candidate , , judgment investigator , adequately respond aggressive sun protection along use potent ( e.g . class I II ) topical corticosteroid and/or immunomodulators Must cutaneous disease activity least `` moderate '' 5 point Likert scale ( use PGA ) Must cutaneous disease activity score least 5 CDASI ( activity ) scale Concurrent therapy topical corticosteroid and/or prednisone and/or antimalarial permit defined Exclusion Criteria . Concurrent therapy methotrexate azathioprine , mycophenolate mofetil , leflunomide permit defined Exclusion Criteria Must meet follow laboratory criterion : Hemoglobin &amp; # 8805 ; 12 g/dL White blood cell ( WBC ) count &amp; # 8805 ; 3000 /uL ( &amp; # 8805 ; 3.0 X 10^9/L ) &lt; 14,000/uL ( &lt; 14 X 10^9/L ) Platelets &amp; # 8805 ; 100,000 /uL ( &amp; # 8805 ; 100 X 10^9/L ) Serum creatinine &amp; # 8804 ; 1.5 mg/dL ( &amp; # 8804 ; 132.6 &amp; # 956 ; mol/L ) Total bilirubin &amp; # 8804 ; 2.0 mg/dL Aspartate transaminase ( AST [ serum glutamic oxaloacetic transaminase , SGOT ] ) alanine transaminase ( ALT [ serum glutamate pyruvic transaminase , SGPT ] ) ; 1.5x upper limit normal ( ULN ) unless , opinion , investigator , elevation secondary active muscle inflammation . Females childbearing potential ( FCBP ) must negative urine pregnancy test screening ( Visit 1 ) . In addition , sexually active FCBP must agree use TWO follow adequate form contraception study medication : oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner . A FCBP must agree pregnancy test every 28 day study medication . Males ( include vasectomy ) must agree use barrier contraception ( latex condom ) engage sexual activity FCBP study medication 84 day take last dose study medication History inadequate response cutaneous DM disease great 2 follow agent : methotrexate , cyclosporine , azathioprine , mycophenolate mofetil , IVIG , leflunomide , cyclophosphamide . History inadequate response thalidomide dermatomyositis skin disease . Receiving topical therapy within 14 day Study Day 0 ( include limited topical corticosteroid , tacrolimus , pimecrolimus ) . Exceptions : low potency corticosteroid allow background therapy treatment face scalp need , dose must stable 14 day prior Study Day 0 throughout study Concurrent therapy prednisone ( equivalent dose systemic corticosteroid ) great 10 mg daily . Concurrent therapy one follow agent : methotrexate , azathioprine , mycophenolate mofetil , leflunomide . Receiving follow dosage medication study within 28 day Study Day 0 : Hydroxychloroquine &gt; 600 mg/day Chloroquine &gt; 400 mg/day Methotrexate &gt; 25 mg/week Mycophenolate mofetil &gt; 3 g/day Azathioprine &gt; 3 mg/kg/day Leflunomide &gt; 20mg/day Treatment follow biologic agent : Adalimumab , etanercept , efalizumab , infliximab within 12 week Study Day 0 study duration IVIG within 12 week Study Day 0 study duration Rituximab within 9 month Study Day 0 study duration Alefacept within 24 week Study Day 0 study duration Have receive fluctuating dos follow medication 28 day Study Day 0 : methotrexate , mycophenolate mofetil , azathioprine , leflunomide , dapsone Have receive fluctuating dos hydroxychloroquine 2 month Study Day 0 Have receive fluctuating dos chloroquine 3 month Study Day 0 Have receive fluctuating dos prednisone within 14 day prior Study Day 0 Received leflunomide &gt; 20 mg/day 6 month prior Study Day 0 Treatment investigational drug therapy within 28 day Study Day 0 biologic therapy within 30 day 5 halflives biologic agent , whichever longer , Study Day 0 Currently receive follow medication : Cyclophosphamide Intravenous immunoglobulin ( IVIG ) Any TNF inhibitor , include adalimumab , etanercept , infliximab , certolizumab Rituximab Efalizumab Cyclosporine Oral FK506 ( tacrolimus ) Thalidomide History clinically significant ( determined investigator ) cardiac , endocrinologic , pulmonary , neurologic , psychiatric , hepatic , renal , hematologic , immunologic , major uncontrolled disease Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study Pregnant breastfeeding Latent Mycobacterium tuberculosis infection indicate positive Purified Protein Derivative ( PPD ) skin test . History active Mycobacterium tuberculosis infection ( subspecies ) within 3 year prior screen visit without documentation successful treatment * Subjects complete treatment least 3 year prior screen lack documentation may enrol study . Subjects complete treatment least 3 year prior screen allow successful treatment complete least 3 year prior screen document available verification History incompletely treat latent Mycobacterium tuberculosis infection indicate : Subject 's medical record document incomplete treatment Mycobacterium tuberculosis Subject 's self report history incomplete treatment Mycobacterium tuberculosis Any clinically significant abnormality 12lead ECG screen Presence hepatitis B surface antigen ( HBsAg ) Hepatitis B core antibody positive screening Antibodies hepatitis C virus screen History human immunodeficiency virus ( HIV ) infection Malignancy history malignancy except treat ( i.e . cure ) basalcell skin carcinoma Abnormal chest xray finding consistent dermatomyositisassociated interstitial lung disease . Chest xrays perform within 3 month prior start study drug acceptable Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>